Modeling the impact of the 13-valent pneumococcal conjugate vaccine serotype catch-up program using United States claims data

摘要

BackgroundAnalysis of US claims data from April 2010 to June 2011 estimated that 39% of the 13-valent pneumococcal conjugate vaccine (PCV13) catch-up eligible cohort would ever receive the catch-up vaccination; a previous analysis assumed 87%.